Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Grasso

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Frontiers in Aging Neuroscience|May 9, 2022
Harnessing the Power of Leptin: The Biochemical Link Connecting Obesity, Diabetes, and Cognitive DeclinePatricia Grasso
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|September 15, 2011
Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogsPatricia Grasso
Regulatory Peptides|September 11, 2012
[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db miceMatthew C Leinung, Patricia Grasso
Regulatory Peptides|February 19, 2011
Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster miceEdward T Maggio, Patricia Grasso
International Journal of Toxicology|August 9, 2023
Assessing the Safety of MA-[D-Leu-4]-OB3, a Synthetic Peptide Leptin Mimetic: Two Pre-Clinical Toxicity Studies in Male and Female C57BL/6 MiceForrest Enemark, Zachary M Novakovic, Patricia Grasso
Peptides|December 3, 2014
Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacyZachary M Novakovic, Brian M Anderson, Patricia Grasso
Regulatory Peptides|May 6, 2008
The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J miceDaniel W Lee, Matthew C Leinung, Patricia Grasso
Regulatory Peptides|December 23, 2009
Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administrationDaniel W Lee, Matthew C Leinung, Patricia Grasso
Peptides|March 19, 2013
[D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance and glycemic regulation in insulin-deficient male Swiss Webster miceZachary M Novakovic, Matthew C Leinung, Patricia Grasso
Brain Research|March 29, 2017
Oral delivery of [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, synthetic peptide leptin mimetics: Immunofluorescent localization in the mouse hypothalamusBrian M Anderson, Lauren Jacobson, Zachary M Novakovic, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Frontiers in Aging Neuroscience|May 9, 2022
Harnessing the Power of Leptin: The Biochemical Link Connecting Obesity, Diabetes, and Cognitive DeclinePatricia Grasso
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|September 15, 2011
Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogsPatricia Grasso
Regulatory Peptides|September 11, 2012
[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db miceMatthew C Leinung, Patricia Grasso
Regulatory Peptides|February 19, 2011
Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster miceEdward T Maggio, Patricia Grasso
International Journal of Toxicology|August 9, 2023
Assessing the Safety of MA-[D-Leu-4]-OB3, a Synthetic Peptide Leptin Mimetic: Two Pre-Clinical Toxicity Studies in Male and Female C57BL/6 MiceForrest Enemark, Zachary M Novakovic, Patricia Grasso
Peptides|December 3, 2014
Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacyZachary M Novakovic, Brian M Anderson, Patricia Grasso
Regulatory Peptides|May 6, 2008
The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J miceDaniel W Lee, Matthew C Leinung, Patricia Grasso
Regulatory Peptides|December 23, 2009
Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administrationDaniel W Lee, Matthew C Leinung, Patricia Grasso
Peptides|March 19, 2013
[D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance and glycemic regulation in insulin-deficient male Swiss Webster miceZachary M Novakovic, Matthew C Leinung, Patricia Grasso
Brain Research|March 29, 2017
Oral delivery of [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, synthetic peptide leptin mimetics: Immunofluorescent localization in the mouse hypothalamusBrian M Anderson, Lauren Jacobson, Zachary M Novakovic, et al.
Pageof 2